Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse

Blood

Volumn 91, Issue 3, 1998, Pages 991-1000

  Kaufmann, Scott H ^a   Karp, Judith E ^b   Svingen, Phyllis A ^b   Krajewski, Stan ^b   Burke, Philip J ^b   Gore, Steven D ^b   Reed, John C ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

POLYPEPTIDE;

APOPTOSIS; ARTICLE; BLAST TRANSFORMATION; CARBOXY TERMINAL SEQUENCE; ENDOPLASMIC RETICULUM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; RELAPSE;

EID: 0032006805     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.3.991.991_991_1000     Document Type: Article

References (74)

1. Dive C, Evans CA, Whetton AD: Induction of apoptosis - New targets for cancer chemotherapy. Semin Cancer Biol 3:417, 1992
2. Sachs L, Lotem J: Control of programmed cell death in normal and leukemic cells: New implications for therapy. Blood 82:15, 1993
3. Kerr JF, Winterford CM, Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013, 1994
4. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89:1845, 1997
5. Mesner P, Budihardjo I, Kaufmann SH: Chemotherapy-induced apoptosis. Adv Pharmacol 41:461, 1997
6. Li X, Gong J, Feldman E, Seiter K, Traganos F, Darzynkiewicz Z: Apoptotic cell death during treatment of leukemias. Leuk Lymph 13:65, 1994
7. Seiter K, Feldman EJ, Halicka HD, Traganos F, Darzynkiewicz Z, Lake D, Ahmed T: Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. J Clin Oncol 15:44, 1997
8. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151, 1993
9. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266:807, 1994
10. Green DR, Bissonnette RP, Cotter TG: Apoptosis and cancer. Import Adv Oncol 37, 1994
11. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ: BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 86:1148, 1995
12. Hickman JA: Apoptosis and chemotherapy resistance. Eur J Cancer 32A:921, 1996
13. Wu GS, El-Deiry WS: Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2. Clin Cancer Res 2:623, 1996
14. Craig RW: The Bcl-2 gene family. Semin Cancer Biol 6:35, 1995
15. Häcker G, Vaux DL: A sticky business. Curr Biol 5:622, 1995
16. Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the Bcl-2 family and cell death. Blood 88:386, 1996
17. Lotem J, Sachs L: Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Leukemia 10:925, 1996
18. Reed JC: Double identity for proteins of the Bcl-2 family. Nature 387:773, 1997
19. Tsujimoto Y, Cossman J, Jaffe E, Croce C: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440, 1985
20. Hockenbery DM, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334, 1990
21. Krajewski K, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC: Investigation of the subcellular distribution of the Bcl-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53:4701, 1993
22. Reed JC: Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7:541, 1995
23. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of Bcl-2 gene expression. Antisense Res Dev 4:71, 1994
24. Keith FJ, Bradbury DA, Zhu YM, Russell NH: Inhibition of Bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 9:131, 1995
25. Pezzella F, Tse AGD: Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 137:225, 1990
26. Zutter M, Hockenberry D, Silverman GA, Korsmeyer SA: Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. Blood 78:1062, 1991
27. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC: Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82:1820, 1993
28. Campana D, Coustan-Smith E, Manabe A, Buschle M, Raimondi SC, Behm FG, Ashmun R, Arico M, Biondi A, Pui C-H: Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of Bcl-2 protein. Blood 81:1025, 1993
29. Gala JL, Vermylen C, Cornu G, Ferrant A, Michaux JL, Philippe M, Martiat P: High expression of Bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis. Ann Hematol 69:17, 1994
30. Coustan-Smith E, Kitanaka A, Pui C-H, McNinch L, Evans WE, Raimondi SC, Behm FG, Arico M, Campana D: Clinical relevance of Bcl-2 overexpression in childhood acute lymphoblastic leukemia. Blood 87:1140, 1996
31. Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzella F, Pierotti MA, Porta GD: Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 79:1291, 1992
32. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud J-P, Guyotat D: High expression of Bcl-2 protein in acute myeloid-leukemia cells is associated with poor response to chemotherapy. Blood 81:3091, 1993
33. Bensi L, Longo R, Vecchi A, Messora C, Garagnani L, Bernardi S, Tamassia MG, Sacchi S: Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica 80:98, 1995
34. Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G: Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 9:1191, 1995
35. Maung ZT, MacLean FR, Reid MM, Pearson ADJ, Proctor SJ, Hamilton PJ, Hall AG: The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Brit J Haematol 88:105, 1994
36. Banker DE, Groudine M, Norwood T, Appelbaum FR: Measurement of spontaneous and therapeutic agent-induced apoptosis with Bcl-2 protein expression in acute myeloid leukemia. Blood 89:243, 1997
37. Reed JC: Bcl-2 family proteins: Strategies for overcoming chemoresistance in cancer. Adv Pharmacol 41:501, 1997
38. Boise LH, González-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao Z, Nuñez G, Thompson CG: Bcl-x, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597, 1993
39. L is the major Bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development 120:3033, 1994
40. L is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 55:2576, 1995
41. L can confer a multidrug resistance phenotype. Blood 86:1903, 1995
42. L by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Diff 6:363, 1995
43. L Overexpression inhibits taxol-induced Yama protease activity and apoptosis. Cell Growth Diff 7:1087, 1996
44. L inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 56:4743, 1996
45. L, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89:2986, 1997
46. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL-2. Proc Natl Acad Sci USA 90:3516, 1993
47. Reynolds JE, Yang T, Qian L, Jenkinson JD, Zhou P, Eastman A, Craig RW: Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 54:6348, 1994
48. Zhou P, Qian L, Kozopas KM, Craig RW: Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89:630, 1997
49. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609, 1993
50. Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang HG: Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 91:9238, 1994
51. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, Korsmeyer SJ: Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 92:7834, 1995
52. L. J Biol Chem 271:22764, 1996
53. L and interleukein-1β converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 10:S18, 1996
54. Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K, Reed JC: Immunohistochemical analysis of Mcl-1 protein in human tissues. Am J Pathol 146:1309, 1995
55. Krajewski S, Krajewska M, Shabaik A, Wang H-G, Irie S, Fong L, Reed JC: Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 54:5501, 1994
56. Bax. J Biol Chem 270:26049, 1995
57. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke PJ: Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83:517, 1994
58. Kaufmann SH, Karp JE, Burke PJ, Gore SD: Addition of etoposide to initial therapy of adult ALL: A combined clinical and laboratory study. Leuk Lymph 23:71, 1996
59. Kaufmann SH, Kellner U: Erasure of western blots after autoradiography or chemiluminescent detection, in Pound J (ed): Methods in Molecular Biology, vol 10, Humana Press, 1997
60. Mariano MT, Moretti L, Donelli A, Grantini M, Montagnani G, Di Prisco AU, Torelli G, Torelli U, Narni F: Bcl-2 gene expression in hematopoietic cell differentiation. Blood 80:768, 1992
61. Park JR, Robertson K, Hickstein DD, Tsai S, Hockenbery DM, Collins SJ: Dysregulated Bcl-2 expression inhibits apoptosis but not differentiation of retinoic acid-induced HL-60 granulocytes. Blood 84:440, 1994
62. Blagosklonny MV, Alvarez M, Fojo A, Neckers LM: Bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells. Leuk Res 20:101, 1996
63. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG: Specific proteolytic fragmentation of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res 53:3976, 1993
64. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG: Bcr-Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179, 1994
65. Kaufmann SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note. Cancer Res 49:5870, 1989
66. Martins LM, Mesner PW, Kottke TJ, Basi GS, Sinha S, Tung JS, Svingen PA, Madden BJ, Takahashi A, McCormick DJ, Earnshaw WC, Kaufmann SH: Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood 90:4283, 1997
67. Sanchez-Garcia I, Grutz G: Tumorigenic activity of the Bcr-Abl oncogenes is mediated by Bcl-2. Proc Natl Acad Sci USA 92:5287, 1995
68. Yang T, Buchan HL, Townsend KJ, Craig RW: MCL-1, a member of the BCL-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation. J Cell Physiol 166:523, 1996
69. Zhan Q, Bieszczaed CK, Bae I, Fornace AJ, Craig RW: Induction of Bcl-2 family member Mcl-1 as an early response to DNA damage. Oncogene 14:1031, 1997
70. Miyashita T, Reed JC: Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407, 1992
71. Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK: Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38:471, 1990
72. Peereboom D, Charron M, Kaufmann SH: Topoisomerases in human leukemia. Adv Pharmacol 29B:33, 1994
73. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, Bhalla K: Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 11:253, 1997
74. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:186, 1995